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In the past decade, Clostridium difﬁcile infections (CDIs) have become a major
public health challenge. Their epidemiology has radically changed with a signiﬁcant
rise in the number of cases and an increase in severe episodes. Recurrence and failure
of conventional treatments are very common. Furthermore, a spread of CDI has
emerged in general population without the usual risk factors (unexposed to antibiotic
treatment, young people, etc.). The conventional treatments (metronidazole and
vancomycin) are still effective and are the ﬁrst-line antibiotics with new recommenda-
tions. New therapeutic strategies are now available. Recent studies show a better
efﬁcacy of vancomycin compared with metronidazole for severe episodes. Fidax-
omicin is a novel antibiotic drug with an efﬁcacy similar to vancomycin and a lower
risk of recurrence. Finally, for relapsing forms, fecal microbiota transplantation (FMT)
seems to be the best option. We determined risk factors for CDI among patients treated
at the infectious diseases ward of our hospital in Pécs. The study included 886 patients
with CDI from 2009 to 2014. The average number of recurrent episodes was 2.16 and
the proportion of severe cases was 66%. Among our patients, 726 (82%) had taken
antibiotics and 769 (86.8%) had been hospitalized in the prior 3 months before
developing CDI. We have found that prior statin use could be a signiﬁcant risk factor
of CDI (OR: 1.7765, 95% CI: 1.3966–2.2597, p< 0.0001). Finally, we present the
comparative efﬁcacy of different types of treatment (metronidazole, vancomycin,
ﬁdaxomicin, and FMT).
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Introduction
Clostridium difﬁcile, a Gram-positive, obligate anaerobic, spore-forming
bacterium, was ﬁrst isolated from the feces of healthy neonates in 1935 [1]. Since
the association between this agent and antibiotic-associated diarrhea has been
recognized in 1978 [2], the interest in this pathogen is increasing. The incidence of
C. difﬁcile infections (CDIs) has increased to epidemic proportion over the past
decades worldwide. Between 1996 and 2003, the prevalence of CDI in the USA
doubled, reaching 61 per 100,000 [3], and the rate of CDI listed as any diagnosis
of hospitalized patients rose from 3.82 per 1,000 discharges in 2000 to 8.75 per
1,000 discharges in 2008 [4]. Clinicians noticed a larger proportion of severe and
recurrent cases occurring in these countries than previously reported. The increas-
ing incidence of such infection can be partly explained by the spread of
ﬂuoroquinolone-resistant strains belonging to the PCR ribotype 027, the produc-
tion of binary toxin [5–7]. The European Study Group of C. difﬁcile reported the
mean incidence of healthcare-associated CDI as 4.1 per 10,000 hospital patient
days [8, 9]. Subsequently, epidemics caused by PCR ribotype 027 strains have
been recognized in the hospitals in many European countries [10]. The changing
epidemiology of CDI is well illustrated with the recent reports of community-
associated infection in patients without predisposing conditions [11]. In a hospital-
based survey, Bauer et al. [12] identiﬁed 65 different ribotypes from isolates, of
which 014/020 (16%), 001 (9%), and 078 (8%) were the most prevalent, whereas
027 was detected in 5% of isolates. PCR ribotypes 018 and 056 were signiﬁcantly
associated with poor disease outcome [12]. In Hungary, we have experienced that
the CDI outbreak has been started in 2009. These facts inspired us to evaluate the
changing epidemiology of CDIs in our ward.
Patients and Methods
We conducted a case–control study at the infectious diseases ward of the
Clinics of University of Pécs. A CDI patient was deﬁned as an adult with at least
three non-formed stool per day and positive test results for C. difﬁcile toxin.
Stool samples were collected at the department and were sent to the stool
laboratory of the National Public Health and Medical Ofﬁcer Service of Baranya
County. At the ﬁrst period, only ELISA tests for detecting toxins and culture
were available. Both examinations were performed by the laboratory in each of
the cases. Later, C. Diff Quik Chek Complete® (TechLab Inc., 2001 Kraft Drive
Blacksburg, VA, USA) was introduced. This is a rapid membrane enzyme
immunoassay for the simultaneous detection of C. difﬁcile glutamate
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dehydrogenase antigen and toxins A and B in a single reaction well. Cultivation
was done only in those cases where the toxin assay had been found negative.
According to international guidelines, severe disease was deﬁned as CDI
being in an intensive care unit, the presence of pseudomembranes upon endo-
scopic examination, or the existence of two or more of the following factors: fever
of more than 38.3 °C, albumin of less than 2.5 mg/dl, white blood cell count of
more than 15,000 μ−1, or a serum creatinine level greater than or equal to 1.5 times
the premorbid level within 48 h of admission.
Controls were randomly selected from those patients of the same ward who
were hospitalized with diagnosis other than CDI. Exclusion criteria were diarrhea
in the past 3 months or previous CDI in the past medical history. Data were
collected on arrival of the patients between January 1, 2009 and December 31,
2014. Medical and laboratory records were retrospectively reviewed both from
case and control patients. Univariate analysis using t-tests for continuous variables
and the chi-square or Fisher’s exact test for categorical variables identiﬁed risk
factors in patients with CDI. A two-tailed p≤ 0.05 was considered statistically
signiﬁcant. Crude odds ratios (ORs) and 95% conﬁdence intervals (CIs) were
calculated for categorical variables.
Results
In this 6-year period, 6,218 hospitalizations were made, of whom 886 (14.2%)
cases were CDI-associated. Rates of CDI have been gradually increasing in our
department. It was rare as a given diagnosis in 2009, it occurred in 271 of our
1,047 patients (25.9%) in 2013 (Figure 1). From the total of 886 cases, 493 (55.6%)
were females and 393 (44.4%) were males. The mean age of the patients was
found to be 70.1 years with the range of 26–92 years. The average number of
recurrent episodes was 2.16 and the proportion of severe cases was 66%. Exposure
to antibiotics (OR: 12.9807, 95% CI: 10.1172–16.6547, p< 0.0001) and
admission to a healthcare facility have been found to be the two biggest risk
factors. Other factors were proton pump inhibitor (PPI) intake (OR: 6.8598,
95% CI: 5.4055–8.7055, p< 0.0001) and statin intake (OR: 1.7765, 95% CI:
1.3966–2.2597, p< 0.0001).
Discussion
Patients with CDI typically have extended lengths-of-stay in hospitals, and
CDI is a frequent cause of large hospital outbreaks of disease [13]. The data
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collected from the database of our ward have shown that CDI outbreak has reached
Southern Hungary in 2010.
The monthly distribution of CDI cases is shown in Figure 2. We used a
geometrical model based on the harmonic technique of Edwards to examine
seasonal variation in CDI occurrence. Analysis was performed by using Episheet.
xls®. The peak-to-low ratio was 1.44 (95% CI: 1.188–1.764) and the peak was on
27th April. A small burden of cases can be recognized during spring–early summer
in each year. It can be explained by the higher antibiotics intake of the population
during the previous months to treat upper respiratory tract infections.
Figure 1. Number of diagnosed CDI cases in our department between 2009 and 2014
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Figure 2. Reported CDI cases by month
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Of the total 886 CDI cases, 726 (83.50%) had taken antibiotics in the
preceding 3 months (OR: 12.9807, 95% CI: 10.1172–16.6547, p< 0.0001)
(Figure 3). We found that 226 (25.51%) cases were community-associated CDI
(Figure 4). Figure 5 shows the proportion of patients by different age groups.
About 64.8% of the patients have taken PPI (OR: 6.8598, 95% CI: 5.4055–
8.7055, p< 0.0001) and 32.1% of them have taken statin (OR: 1.7765, 95% CI:
1.3966–2.2597, p< 0.0001). These ﬁndings correlate with international epidemio-
logical studies, of which many have found an association with PPI and CDI [14, 15],
and this association is conﬁrmed and the evidence that the PPI use increases the
risk of CDI is strengthened by the recent meta-analyses [16–18]. The effect of
statins on the evolution of CDI is not clear. Several studies suggest that prior statin
use can be a protective factor or can be associated with successful treatment
response [19–21]. Saliba et al. [22] have found that the 30-day mortality rate was
lower among current statin users 89/669 (13.3%) compared with 251/1219
(20.6%) in non-users ( p< 0.001). Some other papers have not found such an
association [23] or suggest that statin intake can be a risk factor and that statins
interact with C. difﬁcile toxins A and B causing an increase in the rate and severity
of C. difﬁcile-associated disease (CDAD) [24]. However, it is important to note
that further examinations are needed to prove this hypothesis.
It is important to note that one of the major limitations of this study is the
lack of information regarding the distribution of the different strains. Collecting
any information regarding the distribution of different ribotypes was impossible,
because ribotyping is not a routine test conducted by the laboratory, and our
Figure 3. Occurrence of Clostridium difﬁcile-associated diarrhea, by type of preceding antibiotic
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investigation was retrospective. However, data from Hungary are available in the
international literature [25, 26]. Terhes et al. [26] have examined 150 fecal
samples collected from patients suffering from in the southeastern part of
Hungary. About 80% of the isolates were found to be positive to both tcdA and
Figure 4. Occurrence of Clostridium difﬁcile-associated diarrhea, by type of hospital ward
Figure 5. Number of cases by different age groups
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tcdB. Eight isolates (5.3%) harbored the cdtB gene responsible for the production
of binding component of binary toxin. Only one strain showed the pattern, which
was identical to PCR ribotype 027, four strains belonged to PCR ribotype 078, and
the remainder was PCR ribotype 131 [26].
Treatment of CDI is very complicated, mainly in those cases where
conventional approaches fail to resolve the problem. Recently presented papers
showed that overall metronidazole was inferior to vancomycin, and there is also an
evidence of inferior microbiological efﬁcacy of the previous drug [27]. In addition,
Musher et al. [28] have found that metronidazole therapy alone has a relatively
poor outcome. Later, a systematic literature revealed that ﬁdaxomicin provides
improved sustained cure rates in patients with CDI compared with vancomycin
and metronidazole [29, 30]. Another analysis has shown that metronidazole, as the
ﬁrst-line treatment for CDIs, is less costly. Fecal microbiota transplantation (FMT)
and vancomycin are more effective [31]. We have experienced that in 652 cases
(73.6%), metronidazole alone was effective and in 90 cases (10.2%), the metro-
nidazole therapy was switched to vancomycin, because of its poor effectiveness
and according to the guidelines of CDI [13, 29, 32], we started vancomycin
therapy immediately on the day of the hospitalization in 142 cases (16%).
Fidaxomycin was used just in two cases (0.2%). In our practice, the symptomatic
cure was achieved in 88.5% of patients who received metronidazole and in
95% of patients who received vancomycin. The recurrence rate has been found
higher when metronidazole was used (19.6% vs. 10.1%).
It is important to note that according to Hungarian and international
guidelines [29, 33], in those cases where conventional treatment had failed, we
have done 30 FMTs with an excellent outcome. In our practice, FMT through the
upper gastrointestinal tract was found to have an overall primary cure rate of
89.7% and a secondary cure rate of 96.5% [34].
A meta-analysis has found all-cause mortality at 30 days varied from 9% to
38%. Three studies reported attributable mortality at 30 days, varying from
5.7% to 6.9%. In hospital, mortality ranged from 8% to 37.2% [35]. In our
department during that time, CDI resulted death in 11.9% (106 cases).
During the past decade, C. difﬁcile has become one of the most important
infections and nosocomial problems. Previous antibiotic treatment, elderly, and
immunosuppression are the risk factors. In addition to the earlier observations, we
observed the possible role of prior statin use in higher and more severe CDI
prevalence. However, further examinations are needed to prove this hypothesis.
Similar to the worldwide tendencies in our ward, we could detect important
changes in the course of this disease (i.e., mortality rates, proportion of severe
cases, etc.). In conclusion, we can note that the C. difﬁcile pandemic has reached
Hungary and shows the same features elsewhere in the developed world.
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In treatment strategies, oral metronidazole therapy is recommended as treatment in
initial CDI in mild/moderate disease, because it has been found to be effective, has
the advantage of low cost, and is less likely inducing the selection of vancomycin-
resistant enterococci. Based on studies, guidelines, and our experiences, vanco-
mycin is considered superior to metronidazole in severe cases. FMT seems to be
highly effective in treating multiple recurrent CDI.
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